Trial · NCT03132636
Results by group324
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 324
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Objective Response Rate (ORR) as Assessed by Independent Central Review (ICR) | Group 1: Metastatic BCC (mBCC) | 22.2 | 95% Confidence Interval 12.0 to 35.6 | Percentage of Participants | |
| Objective Response Rate (ORR) as Assessed by Independent Central Review (ICR) | Group 2: Unresectable Locally Advanced BCC (laBCC) | 32.1 | 95% Confidence Interval 22.4 to 43.2 | Percentage of Participants | |
| Objective Response Rate (ORR) Per Investigator Assessment | Group 1: Metastatic BCC (mBCC) | 25.9 | 95% Confidence Interval 15.0 to 39.7 | Percentage of Participants | |
| Objective Response Rate (ORR) Per Investigator Assessment | Group 2: Unresectable Locally Advanced BCC (laBCC) | 36.9 | 95% Confidence Interval 26.6 to 48.1 | Percentage of Participants | |
| Duration of Response (DOR) as Assessed by ICR | Group 1: Metastatic BCC (mBCC) | NA | 95% Confidence Interval 9.8 to NA | Months | |
| Duration of Response (DOR) as Assessed by ICR | Group 2: Unresectable Locally Advanced BCC (laBCC) | NA | 95% Confidence Interval 15.5 to NA | Months | |
| Duration of Response (DOR) Per Investigator Assessment | Group 1: Metastatic BCC (mBCC) | NA | 95% Confidence Interval 9.8 to NA | Months | |
| Duration of Response (DOR) Per Investigator Assessment | Group 2: Unresectable Locally Advanced BCC (laBCC) | 19.6 | 95% Confidence Interval 16.7 to NA | Months | |
| Complete Response (CR) Rate as Assessed by ICR | Group 1: Metastatic BCC (mBCC) | 3.7 | 95% Confidence Interval 0.5 to 12.7 | Percentage of Participants | |
| Complete Response (CR) Rate as Assessed by ICR | Group 2: Unresectable Locally Advanced BCC (laBCC) | 8.3 | 95% Confidence Interval 3.4 to 16.4 | Percentage of Participants | |
| Complete Response (CR) Rate Per Investigator Assessment | Group 1: Metastatic BCC (mBCC) | 3.7 | 95% Confidence Interval 0.5 to 12.7 | Percentage of Participants | |
| Complete Response (CR) Rate Per Investigator Assessment | Group 2: Unresectable Locally Advanced BCC (laBCC) | 8.3 | 95% Confidence Interval 3.4 to 16.4 | Percentage of Participants | |
| Progression Free Survival (PFS) as Assessed by ICR | Group 1: Metastatic BCC (mBCC) | 10.1 | 95% Confidence Interval 4.2 to 15.9 | Months | |
| Progression Free Survival (PFS) as Assessed by ICR | Group 2: Unresectable Locally Advanced BCC (laBCC) | 16.5 | 95% Confidence Interval 8.6 to 21.8 | Months | |
| Progression Free Survival (PFS) Per Investigator Assessment | Group 1: Metastatic BCC (mBCC) | 6.6 | 95% Confidence Interval 4.2 to 8.3 | Months | |
| Progression Free Survival (PFS) Per Investigator Assessment | Group 2: Unresectable Locally Advanced BCC (laBCC) | 18.1 | 95% Confidence Interval 10.4 to 21.3 | Months | |
| Overall Survival (OS) | Group 1: Metastatic BCC (mBCC) | 49.9 | 95% Confidence Interval 28.4 to NA | Months | |
| Overall Survival (OS) | Group 2: Unresectable Locally Advanced BCC (laBCC) | NA | 95% Confidence Interval NA to NA | Months | |
| Change From Baseline of Patient-reported Outcomes in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) | Group 1: Metastatic BCC (mBCC) | Physical Functioning: Change at Cycle 2 Day 1 | -4.88 | Standard Deviation 14.274 | Score on a Scale |
| Change From Baseline of Patient-reported Outcomes in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) | Group 2: Unresectable Locally Advanced BCC (laBCC) | Physical Functioning: Change at Cycle 2 Day 1 | -1.55 | Standard Deviation 12.101 | Score on a Scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03132636/results